FONT-SIZE Plus   Neg

Merck KGaA Says PETACC-8 Study Of Erbitux Shows No Benefit At Interim Analysis

Merck KGaA (MKGAY.PK) revealed results from an interim analysis of the Phase III clinical trial PETACC-81.

The study investigated the potential clinical utility of Erbitux (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor.

The pre-specified interim analysis of the study did not support benefit in disease free survival for patients given Erbitux plus standard chemotherapy (FOLFOX 4) compared with patients treated with FOLFOX 4 alone. Therefore this interim analysis does not support the use of Erbitux for the adjuvant treatment of stage III colon cancer in this setting.

"We are disappointed not to see an improvement in disease free survival after 3.3 years of median follow up" said Professor Julien Taïeb from the Hôpital Européen Georges Pompidou, Paris, and the PETACC-8 Principal Investigator. "Unfortunately, since the introduction of FOLFOX as standard treatment, all attempts to further improve prevention of disease recurrence have proved unsuccessful. We look forward to sharing our data at future scientific congresses."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Earnings at banking giant JP Morgan Chase (JPM) jumped more than 20% compared to last year, despite a decline in revenue. The firm's bottom line received a boost from about $2 billion in tax benefits. Computer chip maker Intel (INTC) announced earnings for the third quarter that slipped about 6 percent from last year. Still, the bottom line came in above the amount predicted by market analysts, as Wall Street had predicted a more pronounced decline. Intel benefited from gains in its Data Center and Internet units, but saw year-over-year weakness in its Client Computing division. Starbucks is rolling out its delivery service - good news for any caffeine addicts who can't make it out to the coffee chain. Unfortunately, there's still a wait in store for most people: the new service only covers Manhattan's most recognizable skyscraper. According to multiple media reports, Starbucks' pilot program is launching at the Empire State Building in New York City.
comments powered by Disqus
Follow RTT